The Australian consumer watchdog agency is taking Novartis (NVS) and GlaxoSmithKline (GSK) to court for allegedly false or misleading marketing about a pair of gels used to treat pain.

The move is the latest by the Australian Competition and Consumer Commission to crack down on drug makers for making “misleading representations” about their products. Last year, the agency fined Reckitt Benckiser $4.5 million for deceptive practices in promoting a pain medication.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • If fading memory serves, Voltaren was ‘a hot new US product’ for CibaGeigy 30 years ago. A new meaning to ‘evergreening!’

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy